LY 2183240

Key Product Details

Product Description

LY 2183240 is a novel and highly potent blocker of anandamide uptake (IC₅₀ = 270 pM). Inhibits fatty acid amide hydrolase (FAAH) activity (IC₅₀ = 12.4 nM). Following i.p. administration in rats, increases brain anandamide concentration and exerts antinociceptive effects in formalin model of pain.

Licensing Information

Sold under license from Eli Lilly and Company

Product Specifications for LY 2183240

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for LY 2183240

The following data is based on the product molecular weight 307.35.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	3.25 mL	16.27 mL	32.54 mL
5 mM	0.65 mL	3.25 mL	6.51 mL
10 mM	0.33 mL	1.63 mL	3.25 mL
50 mM	0.07 mL	0.33 mL	0.65 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 7 publications citing the usage of this product.

• Alexander and Cravat The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. J.Am.Chem.Soc. 2006 PMID: 16866524
• Moore Identification of a high-affinity binding site involved in the transport of endocannabinoids. Proc.Natl.Acad.Sci.USA
• Dickason-Chesterfield Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors. Cell Mol.Neurobiol. 2006 PMID: 16736384

Product Documents for LY 2183240